Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps



Status:Completed
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:50 - 75
Updated:9/2/2018
Start Date:October 1993
End Date:February 2007

Use our guide to learn which trials are right for you!

CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects

Colorectal cancer is a leading cause of cancer death in the United States. Mortality remains
high because most colorectal cancers are detected after there has been regional or distant
spread, precluding curative surgical resection. With this in mind, screening strategies have
been recommended for asymptomatic individuals which hope to reduce mortality from colon
cancer by detecting and removing premalignant adenomatous polyps or early malignant lesions.
Screening of asymptomatic individuals over age 50 with sigmoidoscopy and fecal occult blood
tests has been advocated by the American Cancer Society. However, current screening will
identify only 50% of patients who have adenomatous polyps. More sensitive tests for polyp
detection, like colonoscopy, are costly, require extensive resources and are unlikely to be
used for screening large populations. Ideal screening would identify patients with the
highest risk of cancer and target more sensitive screening tests at this population. The
identification of low cost, easily collectible risk factors which can be used to target
patients for the more sensitive screening tests is the primary purpose of this study. Since a
major segment of the veteran population is over the age of 50, there will be a substantial
impact in reduction of both mortality and morbidity due to colon cancer and attendant cost
savings to the VA for treatment if such risk factors can be identified.

Phase I is a cross-sectional study designed to identify risk factors for large (>1 cm)
adenomatous polyps. Approximately 3200 asymptomatic subjects (age 50-75) have completed risk
factor assessment, medical and dietary histories, and have undergone complete colonoscopy
examination. This will identify for comparison purposes a polyp-free control group and is the
first large prospective study to include such a group. Data at colonoscopy will characterize
the prevalence, size and distribution of adenomatous polyps. This will permit an assessment
of sensitivity of sigmoidoscopy in this population. In addition, tissue from normal rectal
mucosa will be analyzed for evidence of cell proliferation activity. The primary focus of
Phase I is a risk factor analysis. A multivariate analysis will be performed to determine the
relationship of historical and environmental factors as well as cell proliferation activity
with the presence of adenomatous polyps. A cohort consisting of a subgroup of polyp patients
(large and small) and matched polyp-free controls will be tracked longitudinally to determine
polyp occurrence/recurrence rates.

Phase II of the study is a long-term follow-up study designed to evaluate the relative risk
of two repeat colonoscopies.

Phase III is an extension in follow-up of an additional five years, a total of ten years in
all, to include all study patients. The primary focus will be on documenting long-term
mortality and medical outcomes as well as occurrence/reoccurrence of neoplasia with special
emphasis on ten-year cancer rates.

Primary Hypothesis: Risk factors can be determined for large (>1 cm) adenomas, precursor
lesions for colorectal cancer.

Secondary Hypothesis: Determine long-term rates for development or recurrence of polyps;
determine sensitivity/specificity of current colon cancer screening strategies; determine
relationship of dietary factors and biomarkers of cell proliferation; determine the efficacy
and safety of long-term (5 years) repeat colonoscopy in patients with small polyps.

Intervention: Phase I: All patients undergo full colonoscopy. Phase II: Randomization to
repeat colonoscopy at 2-3 years and 5 years after baseline, or, repeat colonoscopy at 5 years
only. Phase III: Ten-year follow-up on all Phase I patients for medical outcomes. Repeat
colonoscopy at 10 years on polyp-free patients (Phase I) aged 50-64.

Primary Outcomes: Presence of risk factors and adenomatous polyps including prevalence,
descriptive characteristics, and long-term occurrence/recurrence rates.

Study Abstract: Phase I is a cross-sectional study designed to identify risk factors for
large (>1 cm) adenomatous polyps. Approximately 3200 asymptomatic subjects (age 50-75) have
completed risk factor assessment, medical and dietary histories, and have undergone complete
colonoscopy examination. This will identify for comparison purposes a polyp-free control
group and is the first large prospective study to include such a group. Data at colonoscopy
will characterize the prevalence, size and distribution of adenomatous polyps. This will
permit an assessment of sensitivity of sigmoidoscopy in this population. In addition, tissue
from normal rectal mucosa will be analyzed for evidence of cell proliferation activity. The
primary focus of Phase I is a risk factor analysis. A multivariate analysis will be performed
to determine the relationship of historical and environmental factors as well as cell
proliferation activity with the presence of adenomatous polyps. A cohort consisting of a
subgroup of polyp patients (large and small) and matched polyp-free controls will be tracked
longitudinally to determine polyp occurrence/recurrence rates.

Phase II of the study is a long-term follow-up study designed to evaluate the relative risk
of two repeat colonoscopy schedules for patients with small polyps identified in Phase I of
the study. Recruitment is complete with 615 patients eligible (of the target 808) assigned at
random to either repeat colonoscopy at 2-3 years and 5 years, or to repeat colonoscopy at 5
years only. This phase will also provide preliminary longitudinal risk factor information
related to occurrence/recurrence of polyps.

Phase III was a 5-year extension of follow-up period. All Phase I patients were to be
reconsented to provide medical outcome data for a period of 10 years from baseline exam.
Phase I patients polyp-free, aged 50-64 will be offered repeat colonoscopy at 10 years to
evaluate long-term risk.

Results (Phase I): 3121 patients had complete colonoscopy which revealed high rates of
neoplasia: 37.5% had one or more neoplastic lesions; 10.5% had advanced neoplasia including
30 cases of invasive cancer (1%). There were 3.7% of patients with no lesions in the rectum
or sigmoid colon who had advanced neoplasia elsewhere in the colon: 32% of all patients with
advanced neoplasia would not be detected with an exam of the rectum or sigmoid colon
(distal); 62% of patients with proximal advanced neoplasia would not be detected with an exam
of the rectum and sigmoid colon. There were few serious complications (0.3%).

The one-time fecal occult blood test (FOBT) was evaluated as a diagnostic test for advanced
neoplasia. A positive FOBT indicated an increased likelihood (3-4x) of advanced neoplasia.
However, one-time FOBT failed to detect 75% of patients with advanced neoplasia.

The primary analysis of risk factors (Phase I) found positive associations (for advanced
neoplasia) for history of a first degree relative with colorectal cancer (OR, 1.66; 95% CI,
1.16-2.35), current smoking (OR, 1.85; 95% CI, 1.33-2.58), and current moderate to heavy
alcohol use (OR, 1.02, 95% CI, 1.01-1.03). Inverse associations were found for cereal fiber
intake (OR, 0.95, 95% CI, 0.91-0.99), vitamin D intake (OR, 0.94, 95% CI, 0.90-0.99), and use
of NSAIDs (OR, 0.66, 95% CI, 0.48-0.91). Results appeared in JAMA (2003;290:2959-2967).

Phase III is completed with patients completing their scheduled follow-ups. A major
manuscript on the sensitivity/specificity of digital rectal exam appeared in Annals of
Internal Medicine January, 2005. The Phase II results manuscript appeared in Gastroenterology
in October 2007.

Inclusion Criteria:

Study Complete

Exclusion Criteria:
We found this trial at
13
sites
3801 Miranda Avenue
Palo Alto, California 94304
650-493-5000
VA Palo Alto Health Care System The VA Palo Alto Health Care System (VAPAHCS) consists...
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Hines, Illinois 60141
?
mi
from
Hines, IL
Click here to add this to my saved trials
Kansas City, Missouri 64128
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Long Beach, California 90822
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55417
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Portland, Oregon 97201
?
mi
from
Portland, OR
Click here to add this to my saved trials
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
White River Junction, Vermont 05009
?
mi
from
White River Junction, VT
Click here to add this to my saved trials